1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6BEC3D32ECB2CD30285257577004A1C26
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/pharmaceutical-early-stage-commercialization-using-portfolio-management-to-drive-success
18
19
2054.174.51.80
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services New Product Development Early stage commercialization

Pharmaceutical Early-Stage Commercialization: Using Portfolio Management to Drive Success

ID: 5026


Features:

5 Info Graphics

10 Data Graphics

186 Metrics

7 Best Practices


Pages/Slides: 32


Published: Pre-2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Pharmaceutical Early-Stage Commercialization: Using Portfolio Management to Drive Success"



STUDY OVERVIEW
The investment decisions that drive product development cycles are exceedingly complex. Even during early-stage development, pharmaceutical companies and their portfolio management teams must balance scientific data with an awareness of what compounds hold the greatest potential market value.

Portfolio management is the linchpin in the precarious act of capital allocation during the early-stage commercialization process and throughout the lifecycle of a product. Portfolio management teams greatly impact the profitability of companies by determining the course of massive investments in R&D and by directing the volume and pace of funding for individual drug development projects.

Best Practices, LLC conducted this research to understand how well-aligned portfolio management teams incorporate both clinical and commercial insights into the early-stage commercialization process. This research also identifies the role played by various commercial functions on investment committees and the functional groups that most often lead investment committees for winning portfolio management teams.

Pharmaceutical executives involved with portfolio management and early commercialization activities can use this study to enhance portfolio decision-making capabilities and to promote functional alignment for early-stage investment decision groups.

NOTE: The data in this research are segmented into two parts: Large Pharma and Full Benchmark Class.

KEY TOPICS

  • Key Findings across the Early-Stage Commercialization Process - Structure, Functions, Relationships and Portfolio Management
  • Oversight of Portfolio Management in Early-Stage Commercialization Process
  • Portfolio Management and Capital Allocation
  • Composition and Leadership of the Investment Decision Committee
  • Commercial Involvement in Early Development Decisions
  • Functional Influence on Issues Presented for Development Decisions

KEY METRICS
  • Global Marketing Responsibility for Early-Stage Commercialization
  • Investment Decision Committee Makeup by Functional Group (Full Benchmark Class & Large Pharma)
  • Functional Groups that Drive Major Investment Decisions [>$100M](Full Class and Large Pharma)
  • Investment Decisions for Phase III Asset by Functional Group (Full Class and Large Pharma)
  • Investment Decisions for Line Extensions by Functional Group (Full Class and Large Pharma)
  • Development Decisions for Launch Monitoring by Functional Group (Full Class and Large Pharma)
  • Post-Launch Product Issue Decisions by Functional Group (Full Class and Large Pharma)
  • Functional Groups that Drive Decisions for In-Licensing a Phase III Asset (Full Class and Large Pharma)

SAMPLE KEY FINDINGS
  • R&D most often leads the early-stage investment (or portfolio management) committee. In all, R&D either leads or co-leads 67 percent of the time within the large pharmaceutical segment, with medical affairs the group that leads second most frequently. Among the full benchmark class, R&D leads or co-leads the invest committee at 56 percent of companies and commercial strategy is the next most likely to lead.
  • R&D is the function that most often drives issues presented for development decisions related to major development investments. In the large pharmaceutical segment, R&D drives issues for decisions on major investment at 45 percent of companies.

METHODOLOGY
This report is based on a biopharmaceutical benchmarking study involving various functions working in the early-stage commercialization space at 20 different biopharma companies. Surveys focused on collecting quantitative data while 11 deep-dive interviews collected qualitative data and management insights.

Industries Profiled:
Pharmaceutical; Biotech; Manufacturing; Consumer Products; Diagnostic; Medical Device; Chemical; Health Care


Companies Profiled:
Abbott Laboratories; Allergan; Alexion Pharmaceuticals; Altus Biologics; Amgen; AstraZeneca; Bayer; Eli Lilly & Co.; Genentech; GlaxoSmithKline; Human Genome Sciences; Intervet International (part of Schering-Plough); Merck; Neurocrine Biosciences; Novartis; Roche; Shire; Solvay Pharamaceuticals; Teva Pharmaceutical Industries; Vertex Pharmaceuticals


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.